NCT03394781终止2 期
A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Durect
- 入组人数
- 5
- 试验地点
- 4
- 主要终点
- Percent Change of Alkaline Phosphatase (ALP) From Baseline
研究概览
简要总结
This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Verified diagnosis of primary sclerosing cholangitis (PSC) for at least 12 months, with or without inflammatory bowel disease (IBD).
- •Serum alkaline phosphatase (ALP) ≥ 1.5 times ULN and with no >15% fluctuation in the past 3 months.
- •In subjects receiving treatment with ursodeoxycholic acid (UDCA), therapy must be stable for at least 3 months and at a dose not greater than 20 mg/kg/day.
- •Subjects of childbearing potential must agree to use a medically acceptable method of contraceptive to prevent pregnancy in the subject and/or the partner for the duration of their participation in the trial up to 2 months after the last study drug dosing.
排除标准
- •Presence of documented secondary sclerosing cholangitis or small duct PSC
- •Bacterial cholangitis within 30 days prior to Screening
- •Presence of percutaneous drain or endoscopic bile duct stent
- •History of, or suspicion of cholangiocarcinoma.
- •Prior liver transplantation, or currently listed for liver transplantation
- •Presence of other concomitant liver diseases
- •Moderate to Severe active IBD or flare in colitis activity within the last 3 months
- •Any severe and/or untreated concomitant cardiovascular, renal, endocrine or psychiatric disorder
- •Any active malignant disease (within 3 years), other than non-melanomatous skin cancer
- •Human immunodeficiency virus (HIV) infection
- •Existing or intended pregnancy, or breast feeding
- •Has received medication from another clinical trial within the past 30 days
研究组 & 干预措施
DUR-928 10 mg
Experimental
10 mg oral suspension
干预措施: DUR-928 (Drug)
DUR-928 50 mg
Experimental
50 mg oral suspension
干预措施: DUR-928 (Drug)
结局指标
主要结局
Percent Change of Alkaline Phosphatase (ALP) From Baseline
时间窗: Day 28 (end of treatment) and Day 56 (end of study/early termination)
次要结局
- Percent Change of Liver Enzymes and Serum Bile Acids (sBA)(Day 28 and Day 56)
- Percent of Subjects With Reduction of Serum Alkaline Phosphatase (ALP) From Baseline(Day 28 (end of treatment) and Day 56 (end of follow-up))
- Percent Change of Selected Biomarkers From Baseline Through the End of Study Treatment and Throughout the Follow-up Period.(Day 28 and Day 56)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) ParticipantsCarcinoma, Non-Small-Cell LungNCT01900652Eli Lilly and Company111
已完成
2 期
A Study of LY3209590 in Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT03736785Eli Lilly and Company399
进行中（未招募）
2 期
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMGlioblastomaNCT03452579David Peereboom90
Unknown
1 期
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer PatientsProstate CancerNCT00895466Pepscan Therapeutics12
撤回
2 期
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic MutationRefractory Follicular LymphomaFollicular LymphomaNCT06068881Epizyme, Inc.55